Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Yervoy
Yervoy
BMS Builds Case for Opdivo, Yervoy Combo in First-Line Colorectal Cancer
BMS Builds Case for Opdivo, Yervoy Combo in First-Line Colorectal Cancer
BioSpace
Bristol Myers Squibb
Opdivo
Yervoy
colorectal cancer
metastatic colorectal cancer
clinical trials
Flag link:
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
CP WIre
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Flag link:
Most-clicked pharma news for week ending March 18 2023: Medtronic offers early retirement package, Novartis to sell ophthalmological assets, and Pfizer tops list of drugs with price increases
Medtronic
Medtech
inflation
drug pricing
Pfizer
Novartis
Merck
Bristol Myers Squibb
Keytruda
Opdivo
Yervoy
lung cancer
Xiidra
JNJ
executive compensation
Flag link:
Bristol Myers doubles down in immuno-oncology patent fight with AZ, this time targeting Imjudo
Bristol Myers doubles down in immuno-oncology patent fight with AZ, this time targeting Imjudo
Fierce Pharma
Bristol Myers Squibb
legal
AstraZeneca
Imjudo
Yervoy
cancer
patents
Flag link:
Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval
Regeneron's Libtayo posts lung cancer win with Bristol's Yervoy. But company won't seek approval
Fierce Pharma
Regeneron
Libtayo
non-small cell lung cancer
Bristol Myers Squibb
Yervoy
Flag link:
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
ESMO: Bristol Myers, Roche fail in post-surgery kidney cancer. But is it good news for Merck's Keytruda?
Fierce Pharma
ESMO
Roche
Bristol Myers Squibb
kidney cancer
Keytruda
Merck
Opdivo
Yervoy
Flag link:
Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?
Exelixis trot out Opdivo-Yervoy-Cabometyx combo win in kidney cancer. Will FDA accept?
Fierce Pharma
Exelixis
Cabometyx
kidney cancer
Opdivo
Yervoy
Bristol Myers Squibb
Flag link:
ESMO: Facing new Keytruda combos from Merck, BMS touts 5-year kidney cancer data for Opdivo-Yervoy
ESMO: Facing new Keytruda combos from Merck, BMS touts 5-year kidney cancer data for Opdivo-Yervoy
Fierce Pharma
Bristol Myers Squibb
Opdivo
Yervoy
kidney cancer
ESMO
Flag link:
Bristol Myers rolls out 3-year data mesothelioma data for Opdivo/Yervoy in first look at ESMO slate
Bristol Myers rolls out 3-year data mesothelioma data for Opdivo/Yervoy in first look at ESMO slate
Endpoints
Bristol Myers Squibb
Opdivo
Yervoy
mesothelioma
Flag link:
Xilio raises $95M to take twists on Yervoy and IL-2 into clinic
Xilio raises $95M to take twists on Yervoy and IL-2 into clinic
Fierce Biotech
Xilio Therapeutics
funding
immunotherapy
clinical trials
cancer
oncology
Yervoy
Flag link:
Merck's Keytruda Proves Better Alone in Combination Trial With BMS' Yervoy
Merck's Keytruda Proves Better Alone in Combination Trial With BMS' Yervoy
BioSpace
Merck
Keytruda
Bristol-Myers Squibb
Yervoy
non-small cell lung cancer
Flag link:
WCLC: With Keytruda-Yervoy data, Merck casts doubt on Opdivo's place in lung cancer
WCLC: With Keytruda-Yervoy data, Merck casts doubt on Opdivo's place in lung cancer
Fierce Pharma
WCLC
Keytruda
Yervoy
Merck
Bristol-Myers Squibb
Flag link:
Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC
Merck pulls the plug on a study evaluating blockbuster Keytruda with Yervoy for NSCLC
Endpoints
Merck
Keytruda
Yervoy
clinical trials
non-small cell lung cancer
Flag link:
Jounce shares crash after it abandons immunotherapy combination trial
Jounce shares crash after it abandons immunotherapy combination trial
Pharmaforum
Jounce Therapeutics
non-small cell lung cancer
Bristol-Myers Squibb
Yervoy
Flag link:
Bristol Myers Squibb Drug Combination Wins FDA Approval for Mesothelioma
Bristol Myers Squibb Drug Combination Wins FDA Approval for Mesothelioma
Motley Fool
Bristol-Myers Squibb
FDA
Opdivo
Yervoy
mesothelioma
Flag link:
Bristol Myers' Opdivo-Yervoy duo slashes mesothelioma death risk by 26%
Bristol Myers' Opdivo-Yervoy duo slashes mesothelioma death risk by 26%
Fierce Pharma
WCLC
lung cancer
mesothelioma
Bristol-Myers Squibb
Opdivo
Yervoy
clinical trials
Flag link:
I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
I-O blockbusters from Merck, BMS and more linked to poor COVID-19 outcomes: study
Fierce Pharma
immuno-oncology
checkpoint inhibitors
Merck
Bristol-Meyers Squibb
COVID-19
Keytruda
Opidvo
Yervoy
Genentech
Tecentriq
AstraZeneca
Imfinzi
Flag link:
FDA approval tracker: several early decisions in May
FDA approval tracker: several early decisions in May
EP Vantage
FDA
Deciphera
Qinlock
Blueprint Medicines
Ayvakit
Eli Lilly
Retevmo
Bristol-Myers Squibb
Opdivo
Yervoy
Flag link:
FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC
FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastatic or recurrent NSCLC
Pharmaceutical Business Review
Bristol-Myers Squibb
Opdvio
Yervoy
metastatic non-small cell lung cancer
Flag link:
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
Ahead of ASCO, Bristol Myers Squibb Announces Results for Three Clinical Trials
BioSpace
Bristol-Myers Squibb
Opdivo
Yervoy
non-small cell lung cancer
ide-cel
Multiple Myeloma
Bluebird Bio
ASCO 2020
Flag link:
Pages
1
2
3
4
5
6
7
next ›
last »